The 55% ORR in heavily pre-treated gynecologic cancers is a strong early efficacy signal that differentiates SIM0505 from standard-of-care options (10-25% ORR in PROC). The manageable safety profile supports dose optimization and pivotal trial planning. Monitor the June 2 KOL event and upcoming dose optimization update in Q1 2027 for further catalysts.
Price Chart
Executive Summary
NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, showing a 55% ORR in gynecologic cancers (52.9% ovarian, 66.7% USC) at therapeutic doses with a manageable safety profile. The company also updated its cash runway guidance, stating existing cash funds operations into Q1 2027. The data is clinically encouraging for a heavily pre-treated population, but the stock has historically not reacted positively to similar neutral-scored filings.
Key Facts
- Phase 1 dose escalation data for SIM0505 (CDH6 ADC) showed 55% ORR (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 weeks follow-up.
- Ovarian cancer ORR was 52.9% (9/17); USC ORR was 66.7% (2/3).
- Safety profile was manageable; Grade 3/4 TEAEs were predominantly hematological; 3 patients discontinued due to TRAEs.
- Company believes existing cash ($29.7M as of March 31, 2026) funds operations into Q1 2027.
- Dose optimization in PROC initiated in May 2026; pivotal trial planning underway.
- FDA granted Fast Track Designation for SIM0505 in PROC.
Financial Impact
No revenue or earnings reported; cash runway of $29.7M into Q1 2027 provides ~9 months of funding at current burn rate.
Risk Factors
- Early-stage data with small sample sizes (n=20 evaluable); ORR may not be durable or replicable in larger trials.
- Cash runway only into Q1 2027; likely need for additional financing before pivotal trial completion.
- Competition from other CDH6 ADCs (e.g., Raludotatug deruxtecan) could limit market opportunity.
- Historical stock performance shows poor follow-through on similar filings, suggesting skepticism from the market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d1.htm | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d3.htm | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d2.htm | 0001104659-26-068604 |
| Document: 0001104659-26-068604-index-headers.html | 0001104659-26-068604 |
| Document: 0001104659-26-068604-index.html | 0001104659-26-068604 |
| Document: 0001104659-26-068604.txt | 0001104659-26-068604 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 11w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 14w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 14w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers